Pattern of care of blood donors with early-uncomplicated hereditary haemochromatosis in a Swiss blood donation centre

Vox Sanguinis

Volumn 106, Issue 2, 2014, Pages 111-117

  Stefashyna, O ^a   Stern, M ^b   Infanti, L ^a   Holbro, A ^a   Tichelli, A ^b   Buser, A ^a   O'Meara, A ^b  

^a Blood Transfusion Centre   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Blood donation; Erythrocytapheresis; Haemochromatosis; HFE mutation; Whole blood donation

Indexed keywords

FERRITIN;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BLOOD DONOR; BLOOD SAMPLING; COST BENEFIT ANALYSIS; CYTAPHERESIS; FEMALE; FERRITIN BLOOD LEVEL; HEALTH CARE; HEALTH CARE PRACTICE; HEMOCHROMATOSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; TREATMENT DURATION; YOUNG ADULT;

BLOOD DONATION; ERYTHROCYTAPHERESIS; HAEMOCHROMATOSIS; HFE MUTATION; WHOLE BLOOD DONATION;

ADULT; AGED; BLOOD COMPONENT REMOVAL; BLOOD DONORS; FEMALE; FERRITINS; HEMOCHROMATOSIS; HUMANS; MALE; MIDDLE AGED; SWITZERLAND; YOUNG ADULT;

EID: 84892871450     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/vox.12078     Document Type: Article

References (36)

1. Finberg KE: Regulation of systemic iron homeostasis. Curr Opin Hematol 2013; 20:208-14
2. Mast AE, Lee TH, Schlumpf KS, et al.: The impact of HFE mutations on haemoglobin and iron status in individuals experiencing repeated iron loss through blood donation*. Br J Haematol 2012; 156:388-401
3. Lucotte G: Celtic origin of the C282Y mutation of hemochromatosis. Blood Cells Mol Dis 1998; 24:433-8
4. Edwards CQ, Griffen LM, Ajioka RS, et al.: Screening for hemochromatosis: phenotype versus genotype. Semin Hematol 1998; 35:72-6
5. Jackson HA, Carter K, Darke C, et al.: HFE mutations, iron deficiency and overload in 10, 500 blood donors. Br J Haematol 2001; 114:474-84
6. Burke W, Thomson E, Khoury MJ, et al.: Hereditary hemochromatosis: gene discovery and its implications for population-based screening. JAMA 1998; 280:172-8
7. Bulaj ZJ, Ajioka RS, Phillips JD, et al.: Disease-related conditions in relatives of patients with hemochromatosis. N Engl J Med 2000; 343:1529-35
8. Beutler E, Felitti VJ, Koziol JA, et al.: Penetrance of 845G-> A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002; 359:211-8
9. Jhang JS, Schwartz J: Phlebotomy or bloodletting: from tradition to evidence-based medicine. Transfusion 2012; 52:460-2
10. Adams PC, Barton JC: Haemochromatosis. Lancet 2007; 370:1855-60
11. Barton JC, McDonnell SM, Adams PC, et al.: Management of hemochromatosis. Hemochromatosis Management Working Group. Ann Intern Med 1998; 129:932-9
12. Falize L, Guillygomarc'h A, Perrin M, et al.: Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases. Hepatology 2006; 44:472-7
13. Powell LW, Dixon JL, Ramm GA, et al.: Screening for hemochromatosis in asymptomatic subjects with or without a family history. Arch Intern Med 2006; 166:294-301
14. Niederau C, Fischer R, Purschel A, et al.: Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996; 110:1107-19
15. McDonnell SM, Preston BL, Jewell SA, et al.: A survey of 2, 851 patients with hemochromatosis: symptoms and response to treatment. Am J Med 1999; 106:619-24
16. Seamark CJ, Hutchinson M: Controversy in primary care: should asymptomatic haemochromatosis be treated? BMJ 2000; 320:1314-7
17. Brissot P, Ball S, Rofail D, et al.: Hereditary hemochromatosis: patient experiences of the disease and phlebotomy treatment. Transfusion 2011; 51:1331-8
18. Jolivet-Gougeon A, Loreal O, Ingels A, et al.: Serum transferrin saturation increase is associated with decrease of antibacterial activity of serum in patients with HFE-related genetic hemochromatosis. Am J Gastroenterol 2008; 103:2502-8
19. Conry-Cantilena C: Phlebotomy, blood donation, and hereditary hemochromatosis. Transfus Med Rev 2001; 15:136-43
20. Leitman SF, Browning JN, Yau YY, et al.: Hemochromatosis subjects as allogeneic blood donors: a prospective study. Transfusion 2003; 43:1538-44
21. Jolivet-Gougeon A, Ingels A, Danic B, et al.: No increased seroprevalence of anti-Yersinia antibodies in patients with type 1 (C282Y/C282Y) hemochromatosis. Scand J Gastroenterol 2007; 42:1388-9
22. Luten M, Roerdinkholder-Stoelwinder B, Rombout-Sestrienkova E, et al.: Red cell concentrates of hemochromatosis patients comply with the storage guidelines for transfusion purposes. Transfusion 2008; 48:436-41
23. Nouel O, Voisin PM, Vaucel J, et al.: [Yersinia enterocolitica septicemia associated with idiopathic hemochromatosis and deferoxamine therapy. A case]. Presse Med 1991; 20:1494-6
24. Khan FA, Fisher MA, Khakoo RA: Association of hemochromatosis with infectious diseases: expanding spectrum. Int J Infect Dis 2007; 11:482-7
25. De Buck E, Pauwels NS, Dieltjens T, et al.: Is blood of uncomplicated hemochromatosis patients safe and effective for blood transfusion? A systematic review. J Hepatol 2012; 57:1126-34
26. European Parliament. Directive 2002/98/EC of the European parliament and the council of 27 January 2003 setting standards of quality and safety for the collection, processing, storage and distribution of human blood and blood components and amending directive 2001/83/EC
27. Kohan A, Niborski R, Daruich J, et al.: Erythrocytapheresis with recombinant human erythropoietin in hereditary hemochromatosis therapy: a new alternative. Vox Sang 2000; 79:40-5
28. Adams PC, Barton JC: How I treat hemochromatosis. Blood 2010; 116:317-25
29. Rombout-Sestrienkova E, van Noord PA, van Deursen CT, et al.: Therapeutic erythrocytapheresis versus phlebotomy in the initial treatment of hereditary hemochromatosis - a pilot study. Transfus Apher Sci 2007; 36:261-7
30. Rombout-Sestrienkova E, Nieman FH, Essers BA, et al.: Erythrocytapheresis versus phlebotomy in the initial treatment of HFE hemochromatosis patients: results from a randomized trial. Transfusion 2012; 52:470-7
31. Gan EK, Powell LW, Olynyk JK: Natural history and management of HFE-hemochromatosis. Semin Liver Dis 2011; 31:293-301
32. Waalen J, Felitti VJ, Gelbart T, et al.: Screening for hemochromatosis by measuring ferritin levels: a more effective approach. Blood 2008; 111:3373-6
33. O'Meara A, Infanti L, Stebler C, et al.: The value of routine ferritin measurement in blood donors. Transfusion 2011; 51:2183-8
34. Stern M, O'Meara A, Infanti L, et al.: Prognostic value of red blood cell parameters and ferritin in predicting deferral due to low hemoglobin in whole blood donors. Ann Hematol 2012; 91:775-80
35. Newman B: Hemochromatosis blood donor programs: marginal for the red blood cell supply but potentially good for patient care. Transfusion 2004; 44:1535-7
36. Pauwels NS, De Buck E, Compernolle V, et al.: Worldwide policies on haemochromatosis and blood donation: a survey among blood services. Vox Sang 2013; 105:121-8